Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction.

Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, Kuroda N, Miyazaki A, Komuro I.

Circ J. 2009 Sep;73(9):1669-73.

2.
3.

Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.

Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, De Luca G.

JACC Cardiovasc Interv. 2014 Aug;7(8):849-56. doi: 10.1016/j.jcin.2014.02.016.

4.

Cystatin C in a high-risk combination.

Iwanaga Y, Miyazaki S.

Circ J. 2009 Sep;73(9):1593-4. No abstract available.

5.

The ratio of contrast volume to glomerular filtration rate predicts in-hospital and six-month mortality in patients undergoing primary angioplasty for ST-elevation myocardial infarction.

Çiçek G, Bozbay M, Açıkgöz SK, Altay S, Uğur M, Köroğlu B, Uyarel H.

Cardiol J. 2015;22(1):101-7. doi: 10.5603/CJ.a2014.0027.

PMID:
24671903
6.

Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty.

Droppa M, Desch S, Blase P, Eitel I, Fuernau G, Schuler G, Adams V, Thiele H.

Clin Res Cardiol. 2011 Nov;100(11):1037-43. doi: 10.1007/s00392-011-0338-8.

PMID:
21710343
7.

Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction.

Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, Magalhães A, Martins SR, Gonçalves S, da Silva PC, Fiúza M, Diogo AN, Pinto FJ.

Am J Cardiol. 2012 May 15;109(10):1431-8. doi: 10.1016/j.amjcard.2012.01.356.

PMID:
22356795
8.

Prognostic value of cardiac time intervals by tissue Doppler imaging M-mode in patients with acute ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Biering-Sørensen T, Mogelvang R, Søgaard P, Pedersen SH, Galatius S, Jørgensen PG, Jensen JS.

Circ Cardiovasc Imaging. 2013 May 1;6(3):457-65. doi: 10.1161/CIRCIMAGING.112.000230.

9.

Cystatin C in acute heart failure without advanced renal impairment.

Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Matsui S, Nomura M, Hishida H, Ozaki Y.

Am J Med. 2009 Jun;122(6):566-73. doi: 10.1016/j.amjmed.2008.10.042.

PMID:
19393984
10.

The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.

Oduncu V, Erkol A, Karabay CY, Kurt M, Akgün T, Bulut M, Pala S, Kirma C.

Coron Artery Dis. 2013 Mar;24(2):88-94. doi: 10.1097/MCA.0b013e32835c46fd.

PMID:
23249632
11.

Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome.

Ristiniemi N, Lund J, Tertti R, Christensson A, Ilva T, Porela P, Pulkki K, Pettersson K.

Clin Biochem. 2012 May;45(7-8):535-40. doi: 10.1016/j.clinbiochem.2012.02.012.

PMID:
22394460
12.

MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.

Lindberg S, Jensen JS, Pedersen SH, Galatius S, Goetze JP, Mogelvang R.

Eur J Prev Cardiol. 2015 Jun;22(6):693-700. doi: 10.1177/2047487314538856.

PMID:
24906365
13.

Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.

Akerblom Å, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA, Steg PG, Storey RF, Åsenblad N, James SK.

Clin Chem. 2012 Jan;58(1):190-9. doi: 10.1373/clinchem.2011.171520.

15.

Plasma B-type natriuretic peptide level can predict myocardial tissue perfusion in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

Seo SM, Kim S, Chang K, Min J, Kim TH, Koh YS, Park HJ, Shin WS, Lee JM, Kim PJ, Chung WS, Seung KB.

Coron Artery Dis. 2011;22(6):405-10. doi: 10.1097/MCA.0b013e3283487dac.

PMID:
21701385
16.

Usefulness of β-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes.

Manzano-Fernández S, López-Cuenca A, Januzzi JL, Parra-Pallares S, Mateo-Martínez A, Sánchez-Martínez M, Pérez-Berbel P, Orenes-Piñero E, Romero-Aniorte AI, Avilés-Plaza F, Valdés-Chavarri M, Marín F.

Am J Cardiol. 2012 Nov 1;110(9):1240-8. doi: 10.1016/j.amjcard.2012.06.027.

PMID:
22818840
18.

Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.

Lee MS, Sillano D, Latib A, Chieffo A, Zoccai GB, Bhatia R, Sheiban I, Colombo A, Tobis J.

Catheter Cardiovasc Interv. 2009 Jan 1;73(1):15-21. doi: 10.1002/ccd.21712.

PMID:
19089930
19.

Early routine angioplasty versus selective angioplasty after successful thrombolysis in acute ST-segment elevation myocardial infarction.

Geng W, Tian X, Fu X, Wang P, Wang Y, Wang X, Li W, Liu X.

Coron Artery Dis. 2013 May;24(3):238-43. doi: 10.1097/MCA.0b013e32835e5c67.

PMID:
23358446
20.

Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus.

Fu Z, Xue H, Guo J, Chen L, Dong W, Gai L, Liu H, Sun Z, Chen Y.

Cardiovasc Diabetol. 2013 Nov 1;12:157. doi: 10.1186/1475-2840-12-157.

Items per page

Supplemental Content

Support Center